|Published||Report Code||Available Format||Pages|
Cell Isolation Market Overview
The global cell isolation market generated $4.6 billion revenue in 2017 and is projected to witness a CAGR of 18.8% during the forecast period, on account of the rising demand for biopharmaceuticals , increasing government funding for cell-based research , and growing research on personalized medicine.
GLOBAL CELL ISOLATION MARKET, BY PRODUCT, $M (2013-2023)
On the basis of product, the cell isolation market is categorized into consumables and instruments. Of the two, the faster growth in the market during the forecast period is expected from consumables, with 19.3% CAGR. This is due to increasing demand for various reagents, kits, media, sera, beads, and disposables for carrying out the cell isolation process.
The cell isolation market is categorized into human and animal cells, on the basis of cell type. Animal cell isolation held a larger share in the market during the historical period, contributing $2.6 billion revenue in 2017. Advancements in stem cell technologies for the treatment of various diseases are expected to drive the market growth of this category.
Based on technique, the cell isolation market is categorized into centrifugation, surface marker, and filtration. The surface marker technique is expected to be the fastest-growing category, with its market advancing at a CAGR of 19.6% during 2018–2023. The surface marker technique is more preferred over centrifugation and filtration techniques due to its non-dependence on the cell density and size.
Based on application, the cell isolation market is categorized into biomolecule isolation, cancer research, stem cell research, tissue regeneration, in vitro diagnostics, and therapeutics. During the historical period, biomolecule isolation held the largest size in the market. This can be attributed to the increasing focus on biological compounds for medicinal purposes.
Research laboratories and institutes; hospitals and diagnostic laboratories; cell banks; and biotechnology and biopharmaceutical companies are the major end users of cell isolation products. During the forecast period, the fastest growth in the cell isolation market is expected from hospitals and diagnostic laboratories, with a CAGR of 19.8%. This can be attributed to the rising incidence of viral and bacterial infections, which is resulting in the increased demand for cell isolation products in hospitals and diagnostic laboratories for bacteria and virus isolation using cell culture.
Geographically, North America held the largest share, accounting for more than 38%, in the cell isolation market in 2017. This can be attributed to the presence of large number of research laboratories, academic institutes, pharmaceutical and biotechnology companies, and hospitals and diagnostic laboratories in the region that carry out extensive research with the help of cell isolation instruments and consumables.
Cell Isolation Market Dynamics
Rising demand for biopharmaceuticals is one of the key factors driving the growth of the cell isolation market. Since the production of biopharmaceuticals is easier than that of pharmaceuticals, they are in high demand in the healthcare industry. Biopharmaceuticals are mainly derived from human, animal, and plant sources; therefore, they require a more effective virus filtration method to avoid contamination from viruses.
According to the National Cancer Institute, approximately 1,735,350 individuals are expected to be diagnosed with cancer in the U.S. in 2018. Protein-based biopharmaceuticals have been observed to effectively diagnose and treat various types of cancer, such as chronic myelogenous leukemia and melanoma. Also, there has been an increase in the use of monoclonal antibodies, as they target abnormal pathways and antigens in the case of cancer. Thus, the use of biopharmaceuticals for the early diagnosis of cancer is expected to contribute to the growth of the cell isolation market in the coming years.
Moreover, growth in the biopharmaceutical industry in developing countries, such as India and China, is contributing to the global market growth, as these countries have a large population base. The Chinese biopharmaceutical industry is more aligned toward providing biosimilar versions, like those available in Western countries, in its domestic market, whereas the Indian biopharmaceutical industry is more inclined toward the production and development of biosimilars and biogenerics for export purposes.
Cell Isolation Market Competitive Landscape
As part of business strategy, companies are launching various products in the cell isolation industry to increase their market share. For instance, in January 2018, Bio-Rad received the 510(k) clearance from the U.S. Food and Drug Administration (USFDA) for the IH-Incubator L and IH-Centrifuge L instruments to be used with the full range of Bio-Rad’s IH-System Gel Reagents for manual blood typing. This can standardize automated and manual typing with one method. The unique design of the two instruments helps maximize biopharmaceutical production efficiency by accommodating both conventional tube and gel blood typing.
Besides, in May 2017, Bio-Rad received the 510(k) clearance from the USFDA for enhanced capability with its IH-Com data management software to manage patient results with the company’s IH-1000 automated blood typing instrument. IH-Com features a powerful data management tool that combines all current and prior results associated with a patient, links instruments together at a lab and at other locations and facilitates data transfer to a laboratory information system.
Some of the other key players operating in the cell isolation market are Terumo Corporation, General Electric Company, Thermo Fisher Scientific Inc., pluriSelect Life Science UG (haftungsbeschränkt) & Co. KG, Danaher Corporation, Merck KGaA, STEMCELL Technologies Inc., Miltenyi Biotec GmbH, and Becton, Dickinson and Company.